Skye Bioscience financials
$1.59−1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating income | -$11.1M | -$12.7M | -$14.9M | -$13.3M | -$18.2M | -$11.8M | -$10.7M | -$5.0M | -$8.4M |
| Net income | -$10.8M | -$12.5M | -$14.4M | -$12.8M | -$17.6M | -$11.1M | -$9.7M | -$3.9M | -$7.9M |
| Net margin | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-2.16 | $-2.56 | $-2.91 | $-2.56 | $-3.52 | $-2.24 | $-1.93 | $-0.80 | $-1.60 |
| EBITDA | -$10.9M | -$12.5M | -$14.7M | -$13.1M | -$18.1M | -$11.6M | -$10.5M | -$4.9M | -$8.4M |
| Operating cash flow | -$7.1M | -$8.6M | -$9.8M | -$13.4M | -$10.7M | -$9.2M | -$8.2M | -$5.3M | -$7.1M |
| Free cash flow | -$7.1M | -$8.6M | -$9.8M | -$13.4M | -$10.7M | -$9.2M | -$8.2M | -$6.8M | -$7.1M |
| Diluted shares | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.1M | 4.9M | 4.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.1M | $8.1M | $5.9M | $18.4M | $23.8M | $46.4M |
| Short-term investments | $2.0M | $9.0M | $19.9M | $16.9M | $24.7M | $12.8M |
| Total debt | $143.1K | $250.3K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $11.0M | $19.4M | $28.3M | $41.3M | $52.2M | $64.8M |
| Total liabilities | $11.5M | $10.4M | $8.3M | $8.5M | $8.5M | $5.5M |
| Shareholders' equity | -$497.3K | $9.0M | $20.0M | $32.8M | $43.7M | $59.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology